Targeting the lung using siRNA and antisense based oligonucleotides

S A Moschos; K Spinks; A E Williams; Mark A Lindsay

doi:10.2174/138161208786898851

Targeting the lung using siRNA and antisense based oligonucleotides

S A Moschos, K Spinks, A E Williams, Mark A Lindsay

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

18 Citations (SciVal)

Abstract

The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.

Original language	English
Pages (from-to)	3620-3627
Number of pages	8
Journal	Current Pharmaceutical Design
Volume	14
Issue number	34
DOIs	https://doi.org/10.2174/138161208786898851
Publication status	Published - 2008

Keywords

in-vivo
antisense
mouse
induced pulmonary-fibrosis
airways
oligonucleotide
induced pneumonopathy
RNA interference
antigen-induced eosinophilia
phosphorothioate
lung
siRNA
airway hyperresponsiveness
gene-expression
vascular endothelium
small interfering rna
common beta-chain

Access to Document

10.2174/138161208786898851

Cite this

@article{7a560a06596545a78c38f8a76c33f265,

title = "Targeting the lung using siRNA and antisense based oligonucleotides",

abstract = "The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.",

keywords = "in-vivo, antisense, mouse, induced pulmonary-fibrosis, airways, oligonucleotide, induced pneumonopathy, RNA interference, antigen-induced eosinophilia, phosphorothioate, lung, siRNA, airway hyperresponsiveness, gene-expression, vascular endothelium, small interfering rna, common beta-chain",

author = "Moschos, {S A} and K Spinks and Williams, {A E} and Lindsay, {Mark A}",

year = "2008",

doi = "10.2174/138161208786898851",

language = "English",

volume = "14",

pages = "3620--3627",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science Publishers B.V.",

number = "34",

}

TY - JOUR

T1 - Targeting the lung using siRNA and antisense based oligonucleotides

AU - Moschos, S A

AU - Spinks, K

AU - Williams, A E

AU - Lindsay, Mark A

PY - 2008

Y1 - 2008

N2 - The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.

AB - The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.

KW - in-vivo

KW - antisense

KW - mouse

KW - induced pulmonary-fibrosis

KW - airways

KW - oligonucleotide

KW - induced pneumonopathy

KW - RNA interference

KW - antigen-induced eosinophilia

KW - phosphorothioate

KW - lung

KW - siRNA

KW - airway hyperresponsiveness

KW - gene-expression

KW - vascular endothelium

KW - small interfering rna

KW - common beta-chain

UR - http://www.benthamdirect.org/

UR - http://dx.doi.org/10.2174/138161208786898851

U2 - 10.2174/138161208786898851

DO - 10.2174/138161208786898851

M3 - Article

SN - 1381-6128

VL - 14

SP - 3620

EP - 3627

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

IS - 34

ER -

Targeting the lung using siRNA and antisense based oligonucleotides

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this